Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted) (2024 - 2025)

Silence Therapeutics (SLN) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$0.09 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 200.0% to -$0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.63 through Dec 2025, down 96.87% year-over-year, with the annual reading at -$0.63 for FY2025, 90.91% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.09 in Q4 2025 for Silence Therapeutics, up from -$0.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q4 2024 to a low of -$0.25 in Q3 2024.